
LYNOZYFIC™
(linvoseltamab-gcpt) Injection 5mg | 200mg

YOUR LYNOZYFIC

TREATMENT GUIDE

A resource to understand your treatment with LYNOZYFIC for relapsed or refractory multiple myeloma.



What is LYNOZYFIC?

LYNOZYFIC is a prescription medicine used to treat adults with multiple myeloma who:

- have already received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody to treat their multiple myeloma, **and**
- their cancer has come back or did not respond to prior treatment.

It is not known if LYNOZYFIC is safe and effective in children.

The conditional approval of LYNOZYFIC is based on response rate and durability of response. There are ongoing studies to establish how well the drug works.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about LYNOZYFIC?

LYNOZYFIC may cause serious or life-threatening side effects, including Cytokine Release Syndrome (CRS) and infusion-related reactions (IRR), or neurologic problems.

Cytokine Release Syndrome (CRS) and infusion related reactions (IRR). CRS is common during treatment with LYNOZYFIC and can also be serious or life-threatening. Tell your healthcare provider or get medical help right away if you develop any signs or symptoms of CRS or IRR, including:

- fever of 100.4°F (38°C) or higher
- chills or shaking
- trouble breathing
- fast heartbeat
- dizziness or light-headedness

Please see additional IMPORTANT SAFETY INFORMATION throughout and accompanying full Prescribing Information, including Boxed WARNING, and Medication Guide for LYNOZYFIC.

Actor portrayal.

TABLE OF **CONTENTS**

Is it time for LYNOZYFIC? 3

Results with LYNOZYFIC 4

What to expect with LYNOZYFIC 6

Potential side effects of LYNOZYFIC 8

LYNOZYFIC Surround™ 12

Resources and care coordination 13

Summary 16

Important Safety Information (cont'd) 17

Your LYNOZYFIC calendar 20

IMPORTANT SAFETY INFORMATION (cont'd)

What is the most important information I should know about LYNOZYFIC? (cont'd)

Neurologic problems. LYNOZYFIC can cause neurologic problems that can be serious or life-threatening. Tell your healthcare provider or get medical help right away if you develop any signs or symptoms of neurologic problems, including:

- headache
- agitation, trouble staying awake, confusion or disorientation, seeing or hearing things that are not real (hallucinations)
- trouble speaking, writing, thinking, remembering things, paying attention, or understanding things
- problems walking, muscle weakness, shaking (tremors), loss of balance, or muscle spasms
- numbness and tingling (feeling like "pins and needles")
- burning, throbbing, or stabbing pain
- changes in your handwriting
- seizures


Please see additional IMPORTANT SAFETY INFORMATION throughout and accompanying full Prescribing Information, including Boxed WARNING, and Medication Guide for LYNOZYFIC.

IS IT TIME FOR LYNOZYFIC?

Over the course of your experience with multiple myeloma (MM), your cancer can come back (relapse) or not respond to a treatment (refractory). If you have already received 4 or more treatment regimens and your cancer has come back or has not responded, it may be time to talk to your doctor about LYNOZYFIC.

How does LYNOZYFIC work?

LYNOZYFIC is part of a class of treatments called "BCMA-targeted bispecific antibodies."
This type of treatment works differently from chemotherapy, stem cell transplant, or CAR-T therapy.



LYNOZYFIC is designed to act as a bridge between CD3, a protein on the surface of T cells (a type of immune cell), and BCMA, a protein overexpressed on the surface of multiple myeloma cells and found on some normal plasma cells.

This can activate your immune system to help destroy the multiple myeloma cells.

How do I know if I'm a candidate for LYNOZYFIC?

- **LYNOZYFIC may be an appropriate option if you have already received 4 or more treatment regimens and your cancer has come back or did not respond to prior treatment.** Prior treatments may include:
  - A proteasome inhibitor, such as bortezomib, carfilzomib, or ixazomib
  - An immunomodulatory agent, such as lenalidomide, pomalidomide, or thalidomide
  - An anti-CD38 monoclonal antibody, such as daratumumab or isatuximab
- **Discuss with your doctor** how LYNOZYFIC may fit into your overall treatment plan

BCMA, B-cell maturation antigen; CAR-T, chimeric antigen receptor T cell; CD3, cluster of differentiation 3; CD38, cluster of differentiation 38.

LYNOZYFIC™ (linvoseltamab-gcpt) Injection 5mg | 200mg

A BROAD RANGE OF PATIENTS PARTICIPATED IN THE CLINICAL TRIAL FOR LYNOZYFIC

Responses with LYNOZYFIC were studied in 80 patients with relapsed or refractory multiple myeloma who had received at least 4 prior treatment regimens, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody

- 30% of patients were **aged 75 years or older**
- 40% of patients had **high cytogenetic risk**, meaning they had abnormalities in their genes that made their prognosis worse
- 14% of patients were **Black or African American**
- 13% of patients were **Asian**
- 2.5% of patients were **Hispanic or Latino**

7 of 10 patients (70%, 56/80) responded to treatment with LYNOZYFIC



45% (36/80) **of patients achieved a complete response or better.**
- A **complete response** means that, among other criteria, they had no sign of M protein, an abnormal protein that shows up in people with multiple myeloma

19% (15/80) **of patients achieved a very good partial response.**
- A **very good partial response** means that, among other criteria, they experienced at least a 90% reduction of M protein in the blood

6% (5/80) **of patients achieved a partial response.**
- A **partial response** means that, among other criteria, they experienced at least a 50% reduction of M protein in the blood and a 90% reduction of M protein in urine

TIMING OF RESPONSES WITH LYNOZYFIC

Of the patients in the clinical trial who responded to LYNOZYFIC (56/80), half began seeing results within approximately 1 month of starting treatment.
- The time until patients started to see results ranged from 2 weeks to 6 months

72% of patients who saw improvement with LYNOZYFIC were estimated to still be responding to their treatment at 1 year.
- This is known as the duration of response. This means that, for patients who responded to LYNOZYFIC, the likelihood of them still responding to treatment at 1 year was 72%
- These responses are ongoing and may change in the future as researchers continue to look at results from the clinical trial

IMPORTANT SAFETY INFORMATION (cont'd)

What is the most important information I should know about LYNOZYFIC? (cont'd)

Due to the risk of CRS and neurologic problems, you will receive LYNOZYFIC on a "step-up dosing schedule" and should be hospitalized for 24 hours after the first and second "step-up" doses.

- During the "step-up dosing schedule":
  - For your first dose, you will receive a smaller "step-up" dose of LYNOZYFIC on Day 1 of your treatment.
  - For your second dose, you will receive a larger "step-up" dose of LYNOZYFIC, which is usually given on Day 8 of your treatment.
  - For your third dose, you will receive the first treatment dose of LYNOZYFIC, which is usually given on Day 15 of your treatment.
- Your healthcare provider may repeat one or both of the "step-up" doses depending on side effects or if your treatment is delayed.
- Before the "step-up" doses and the first two treatment doses of LYNOZYFIC, you will receive medicines to help reduce your risk of CRS and IRR. Your healthcare provider will decide if you need to receive medicine to help reduce your risk of side effects with future doses.

LYNOZYFIC is available only through the LYNOZYFIC Risk Evaluation and Mitigation Strategy (REMS) due to the risk of side effects of CRS and neurologic problems. You will receive a Patient Wallet Card from your healthcare provider. **Carry the LYNOZYFIC Patient Wallet Card with you at all times and show it to all of your healthcare providers.** The LYNOZYFIC Patient Wallet Card lists signs and symptoms of CRS and neurologic problems. **Get medical help right away if you develop any of the signs and symptoms listed on the LYNOZYFIC Patient Wallet Card.** You may need to be treated in a hospital.

Please see additional IMPORTANT SAFETY INFORMATION throughout and accompanying full Prescribing Information, including Boxed WARNING, and Medication Guide for LYNOZYFIC.

LYNOZYFIC™ (linvoseltamab-gcpt) Injection 5mg | 200mg


WHAT TO EXPECT WITH LYNOZYFIC

How will I receive LYNOZYFIC?

LYNOZYFIC is a ready-to-use treatment. This means you don't need to wait for personalized manufacturing once your doctor decides to start you on LYNOZYFIC.

- LYNOZYFIC is an intravenous infusion, which means it's given through a needle placed in your vein
- Your doctor will decide how long you will receive treatment with LYNOZYFIC by assessing your response and side effects

Dosing Schedule



*Your doctor will decide if your disease is responding well enough to treatment (a very good partial response or better) to switch to once-every-4-weeks dosing.
†Your infusions may be longer, depending on your side effects.

For the first 2 weeks of treatment, you will receive lower "step-up" doses of LYNOZYFIC to help your body adjust to the treatment and to gradually work up to the full dose.

- **Due to the risk of side effects, it is important to receive the step-up dosing as recommended**

After the first 2 lower step-up doses, the recommended full dose of LYNOZYFIC is given 1 time each week for 12 doses, followed by 1 time every 2 weeks for 5 doses.

After around 19 doses (roughly 6 months), your doctor will decide if you are able to receive LYNOZYFIC less often (once every 4 weeks) or if you will continue to have treatment every other week.

- **This decision is made based on how your disease responds to treatment. If you have a very good partial response or better, you may be able to switch to once-every-4-weeks dosing**
- **If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment**

WHAT TO EXPECT WITH LYNOZYFIC (cont'd)

Additional medications

Before the "step-up" doses and the first two treatment doses of LYNOZYFIC, you will receive medicines, such as a steroid, antihistamine, and fever reducer, to help reduce your risk of CRS and IRR.

Your healthcare provider will decide if you need to receive medicine to help reduce your risk of side effects with future doses.

Talk to your doctor about monitoring for side effects.

- Due to the risk of CRS and neurologic problems, **you should be hospitalized for 24 hours after the first and second "step-up" doses**
- You should continue to report any side effects to your doctor throughout treatment

LYNOZYFIC is the only bispecific treatment for relapsed or refractory multiple myeloma with:

A **dosing schedule of once every 2 weeks**, starting at around 4 months, **regardless of how well your disease responds to LYNOZYFIC.**

The potential for your doctor to switch you to **once-every-4-weeks dosing**, if you have a very good partial response or better, starting at around 6 months.

IMPORTANT SAFETY INFORMATION (cont'd)

What is the most important information I should know about LYNOZYFIC? (cont'd)

Your healthcare provider will monitor you for signs and symptoms of CRS and neurologic problems during treatment with LYNOZYFIC, as well as other side effects, and may treat you in a hospital if needed. Your healthcare provider may temporarily stop or completely stop your treatment with LYNOZYFIC if you develop CRS, neurologic problems, or any other severe side effects.

If you have any questions about LYNOZYFIC, ask your healthcare provider.

Before receiving LYNOZYFIC, tell your healthcare provider about all of your medical conditions, including if you:

- have an infection.
- are pregnant or plan to become pregnant. LYNOZYFIC may harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with LYNOZYFIC.

  Females who are able to become pregnant:

  – Your healthcare provider should do a pregnancy test before you start treatment with LYNOZYFIC.

  – You should use an effective form of birth control (contraception) during treatment with LYNOZYFIC and for 3 months after your last dose of LYNOZYFIC.
- are breastfeeding or plan to breastfeed. It is not known whether LYNOZYFIC passes into your breast milk. Do not breastfeed during treatment with LYNOZYFIC and for 3 months after your last dose of LYNOZYFIC.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see additional IMPORTANT SAFETY INFORMATION throughout and accompanying full Prescribing Information, including Boxed WARNING, and Medication Guide for LYNOZYFIC.

LYNOZYFIC™ (linvoseltamab-gcpt) Injection 5mg | 200mg

POTENTIAL SIDE EFFECTS OF LYNOZYFIC

LYNOZYFIC may cause serious or life-threatening side effects, including:

- Cytokine release syndrome (CRS)
- Infusion-related reactions (IRR)
- Neurologic problems

CRS and IRR

Tell your healthcare provider or get medical help right away if you develop any signs or symptoms of CRS or IRR, which are listed below, at any time during your treatment with LYNOZYFIC.



Some side effects can be signs of immune reactions called CRS or IRR.

- CRS can occur when your immune system becomes overly active. This may happen after treatment with certain medicines that activate the T cells in your immune system
- IRR can happen when your immune system has a strong reaction to a medication given by IV infusion
- CRS is common during treatment with LYNOZYFIC and can also be serious or life-threatening. Signs and symptoms of CRS or IRR may include:
  - fever of 100.4°F (38°C) or higher
  - dizziness or lightheadedness
  - chills or shaking
  - fast heartbeat
  - trouble breathing
- In the clinical trial, CRS occurred in 46% of patients and could be serious or life-threatening. IRR occurred in 9% of patients
  - 45% of all patients in the clinical trial experienced mild or moderate CRS (Grade 1-2). There was 1 case (0.9% of patients) of severe CRS (Grade 3)

Because of the risk of CRS and neurologic problems, you should be hospitalized for 24 hours after receiving your first and second "step-up" doses.



To be prepared for potential side effects, be sure to always carry your LYNOZYFIC Patient Wallet Card with you.

LYNOZYFIC is available only through the LYNOZYFIC Risk Evaluation and Mitigation Strategy (REMS) due to the risk of side effects of CRS and neurologic problems. You will receive a Patient Wallet Card from your healthcare provider. Carry the LYNOZYFIC Patient Wallet Card with you at all times and show the card to any healthcare professional involved in your care. If you go to the emergency room, it includes information needed to contact your LYNOZYFIC treating oncologist. It also lists signs and symptoms of CRS and neurologic problems to look out for. Get medical help right away if you develop any of the signs and symptoms listed on the LYNOZYFIC Patient Wallet Card. You may need to be treated in a hospital.

POTENTIAL SIDE EFFECTS OF LYNOZYFIC (cont'd)

Neurologic problems

Call your healthcare provider or get medical help right away if you develop any of the signs or symptoms of neurologic problems listed below at any time during your treatment with LYNOZYFIC.



Some side effects can be signs of neurologic problems.

- LYNOZYFIC can cause neurologic problems that can be serious or life-threatening
- Signs and symptoms of neurologic problems may include:
  - headache
  - agitation, trouble staying awake, confusion or disorientation, seeing or hearing things that are not real (hallucinations)
  - trouble speaking, writing, thinking, remembering things, paying attention, or understanding things
  - problems walking, muscle weakness, shaking (tremors), loss of balance, or muscle spasms
  - numbness and tingling (feeling like "pins and needles")
  - burning, throbbing, or stabbing pain
  - changes in your handwriting
  - seizures
- In the clinical trial, neurologic problems occurred in 54% of patients treated with LYNOZYFIC
  - 8% of patients experienced severe neurologic side effects (Grade 3 or 4)

Caregivers, you know your loved one best. You may notice changes or symptoms before healthcare providers notice them.

If you think you are seeing signs or symptoms of a side effect, contact their healthcare provider or certified healthcare facility right away.

IMPORTANT SAFETY INFORMATION (cont'd)

How will I receive LYNOZYFIC?

- LYNOZYFIC will be given to you by your healthcare provider by infusion through a needle placed in a vein (intravenous infusion).

Please see additional IMPORTANT SAFETY INFORMATION throughout and accompanying full Prescribing Information, including Boxed WARNING, and Medication Guide for LYNOZYFIC.

LYNOZYFIC™ (linvoseltamab-gcpt) Injection 5mg | 200mg

POTENTIAL SIDE EFFECTS OF LYNOZYFIC



Infections

Bacterial, viral, or fungal infections are a possible side effect with LYNOZYFIC treatment and can be serious, life-threatening, or may lead to death.

- LYNOZYFIC can affect the ability of the immune system to fight infections
- Upper respiratory tract infections and pneumonia are common during treatment with LYNOZYFIC
- Your healthcare provider will monitor you for signs and symptoms of infection before and during treatment with LYNOZYFIC
- Your healthcare provider may prescribe medicines for you to help prevent infections and treat you as needed if you develop an infection during treatment with LYNOZYFIC
- Tell your healthcare provider right away if you get a fever of 100.4°F (38°C) or higher, chills, cough, shortness of breath, chest pain, sore throat, pain during urination, feeling weak or generally unwell, or any other signs or symptoms of an infection



Decreased white blood cell counts

Decreased white blood cell counts are common with LYNOZYFIC and can also be severe.

- Fever can happen with low white blood cell counts and may be a sign that you have an infection
- Your healthcare provider will check your blood cell counts before you start treatment and during treatment with LYNOZYFIC and will treat you as needed

IMPORTANT SAFETY INFORMATION (cont'd)

How will I receive LYNOZYFIC? (cont'd)

- After the "step-up dosing schedule", the treatment dose of LYNOZYFIC is usually given 1 time each week for 11 doses, and then 1 time every other week for 5 doses. After these doses and based on how your disease responds, your healthcare provider will decide if you are able to receive LYNOZYFIC less often (every 4 weeks) or will continue to have every other week treatment.

Please see additional IMPORTANT SAFETY INFORMATION throughout and accompanying full Prescribing Information, including Boxed WARNING, and Medication Guide for LYNOZYFIC.

POTENTIAL SIDE EFFECTS OF LYNOZYFIC (cont'd)



Liver problems

LYNOZYFIC can cause increased liver enzymes and bilirubin in your blood.

These increases can happen with or without you also having CRS.

- Your healthcare provider will do blood tests to check your liver before starting and during treatment with LYNOZYFIC
- Tell your healthcare provider if you develop any of the following signs or symptoms of liver problems:
  - tiredness
  - loss of appetite
  - pain in your right upper stomach-area (abdomen)
  - dark urine
  - yellowing of your skin or the white part of your eyes



Other side effects and lab test results

Other side effects may occur with LYNOZYFIC. The most common side effects include:

- muscle and bone pain
- diarrhea
- tiredness or weakness
- nausea
- headache
- shortness of breath
- cough

The most common severe abnormal blood results with LYNOZYFIC include low white blood cell counts and low red blood cell counts.

These are not all of the possible side effects with LYNOZYFIC.

Call your healthcare provider for medical advice about side effects.
You may report side effects to the FDA at 1-800-FDA-1088.

LYNOZYFIC™ (linvoseltamab-gcpt) Injection 5mg | 200mg

LYNOZYFIC SURROUND™

When you need extra support, LYNOZYFIC Surround may be able to help.

LYNOZYFIC Surround offers financial and educational resources to help support you throughout your treatment journey.

For more information, call LYNOZYFIC Surround at 1.844.RGN.HEME (1.844.746.4363), Option 1, Monday–Friday, 8 AM–8 PM Eastern time.

LYNOZYFIC Surround Commercial Copay Program

You may be eligible to pay as little as **$0 out of pocket** with the LYNOZYFIC Surround Commercial Copay Program.

You may qualify if you:

- Have private (commercial) insurance
- Are a resident of the United States or its territories or possessions

Other conditions may apply.

The LYNOZYFIC Surround Commercial Copay Program provides:

- Up to $25,000 in assistance per year for eligible out-of-pocket expenses for LYNOZYFIC, which includes copay, coinsurance, and deductibles for LYNOZYFIC product and administration charges*

You pay*:

- As little as $0 for LYNOZYFIC until your expenses reach $25,000
- Any additional costs after you reach the program's limit
- Any nonqualifying expenses, such as supplies

There is no income requirement to qualify for this program.

LYNOZYFIC Surround Patient Assistance Program

If you do not have insurance or your insurance does not cover LYNOZYFIC, or if you have Medicare and cannot afford your out-of-pocket costs, you may be eligible to **receive LYNOZYFIC at no cost.†**

You may qualify if you:

- Are uninsured, underinsured, or lack coverage for LYNOZYFIC
- Are a resident of the United States or its territories or possessions
- Demonstrate financial need based on annual household income criteria
- This program only applies to patients treated as an outpatient by a licensed US healthcare provider

Other conditions may apply.

LYNOZYFIC Surround can help evaluate your eligibility for assistance. We also may be able to identify other independent, third-party financial assistance resources.

*Subject to annual maximum copay assistance amount of $25,000 toward out-of-pocket treatment costs for LYNOZYFIC, including deductibles, copays, and coinsurance for LYNOZYFIC drug and administration charges. This program is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, Veterans Affairs/Department of Defense, TRICARE, or similar federal or state programs. Not a debit card program. The program does not cover or provide support for supplies for LYNOZYFIC. Patients who are residents of Massachusetts or Rhode Island are not eligible for LYNOZYFIC administration assistance. This program only applies to patients who are at least 18 years of age, residents of the United States or its territories or possessions, are prescribed LYNOZYFIC (linvoseltamab-gcpt) for an FDA-approved indication, and are insured by a commercial health plan that requires a copayment, coinsurance, and/or deductible amount for LYNOZYFIC. It is not an insurance benefit. LYNOZYFIC Surround reserves the right to rescind, terminate, or amend this offer, eligibility, and terms and conditions at any time without notice. Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this offer. This offer is not conditioned on any past, present, or future purchase, including refills. This offer is nontransferable, limited to one per person, and cannot be combined with any other offer or discount. This program is not valid where prohibited by law, taxed, or restricted. Offer has no cash value. Patients are responsible for any out-of-pocket costs for LYNOZYFIC that exceed the program assistance limit of $25,000 per year. Program is not valid for cash-paying customers. Additional program conditions may apply.

†Eligible patients will be enrolled for up to 12 months; eligible Medicare patients will be enrolled until the end of the calendar year. Patients must reapply annually.

RESOURCES AND CARE COORDINATION

Living with multiple myeloma can be hard, but you don't have to do it alone.

Your healthcare provider is your trusted source for information about your condition and treatment. But we know you may have other questions. Our Patient Navigators are available to offer more information or additional assistance. They can:

- **Identify support groups** within your community if you need encouragement from others or are looking for disease education
- Provide information about other organizations that may offer independent, third-party **transportation services** if you need help getting to your appointments
- Connect you with independent third parties that can offer information about **local places to stay** if needed during treatment
- **Answer questions** about available resources and support
- Remind you about your **upcoming appointments** to help keep you on track with your treatment schedule

You can speak with a Patient Navigator by calling LYNOZYFIC Surround at 1.844.RGN.HEME (1.844.746.4363), Option 1, Monday–Friday, 8 AM–8 PM Eastern time.

IMPORTANT SAFETY INFORMATION (cont'd)

How will I receive LYNOZYFIC? (cont'd)

- Your healthcare provider will decide how long you will receive treatment with LYNOZYFIC.
- If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. It is important for you to be monitored closely for side effects during treatment with LYNOZYFIC.

Please see additional IMPORTANT SAFETY INFORMATION throughout and accompanying full Prescribing Information, including Boxed WARNING, and Medication Guide for LYNOZYFIC.

LYNOZYFIC™ (linvoseltamab-gcpt) Injection 5mg | 200mg

RESOURCES AND CARE COORDINATION (cont'd)

Independent organizations may be able to provide you with online or in-person peer support. They offer support groups and seminars, one-on-one mentorship, and guidance from patients and caregivers going through the same experience, along with opportunities to get involved in advocacy and events.

Organizations:

Cancer Support Community
cancersupportcommunity.org | 1-888-793-9355

Cancer*Care*
cancercare.org | 1-800-813-4673

HealthTree Foundation
healthtree.org/myeloma | 1-800-709-1113

International Myeloma Foundation
myeloma.org | 1-818-487-7455

Multiple Myeloma Research Foundation
themmrf.org | 1-888-841-6673

The Leukemia & Lymphoma Society
LLS.org | 1-800-955-4572

Transportation to and from appointments can be expensive and difficult to coordinate. Independent organizations may be able to help you access hospital-run or local programs that may offer rides, gas cards, or travel and housing assistance.

These independent organizations include:

- The Multiple Myeloma Research Foundation
- ITN*America*
- The Lazarex Cancer Foundation

The inclusion of the independent nonprofit organizations listed above does not imply endorsement of LYNOZYFIC or Regeneron.

IMPORTANT SAFETY INFORMATION (cont'd)

What should I avoid while receiving LYNOZYFIC?

Do not drive, or operate heavy or potentially dangerous machinery, or do other dangerous activities for 48 hours after completing each of your "step-up" doses or at any time during treatment with LYNOZYFIC if you develop new neurologic symptoms, until the symptoms go away.

Please see additional IMPORTANT SAFETY INFORMATION throughout and accompanying full Prescribing Information, including Boxed WARNING, and Medication Guide for LYNOZYFIC.

RESOURCES AND CARE COORDINATION (cont'd)

Managing the costs of care can be a source of stress for patients and caregivers.

In addition to LYNOZYFIC Surround, you may be able to receive financial assistance for your treatment from independent organizations.
These organizations may be able to help you plan how to pay nonmedical expenses, such as mortgage or rent, childcare, utilities, dental care, and more.

RE ASSIST* is an independent charitable foundation resource that helps people with multiple myeloma to identify potential sources of independent, third-party funding for treatment and treatment-related expenses.
RE ASSIST is updated in real time, so check back often for new listings!

Access RE ASSIST at LYNOZYFIC.com.

*RE ASSIST is an independent third-party not affiliated with Regeneron. Regeneron does not develop the content, is not responsible for the accuracy of the information provided, and does not endorse any particular charitable foundation.


Actor portrayal.

For caregivers:

While you're taking care of your loved one, it's also important to take care of yourself. The organizations listed on the previous page may help you manage the challenges of caring for someone with multiple myeloma.

- Grieving a loved one's diagnosis and caring for someone with a serious illness can be isolating, but you are not alone
  - Consider joining or starting a caregiver support group for a place to express yourself and share your story. The International Myeloma Foundation may be able to help connect you to a group in your area or provide resources and assistance for starting your own
- There is no shame in sharing the load. Managing the demands of multiple myeloma treatment takes a village. Identify friends or family who can help you. You might use shared resources, such as trackers, planners, and checklists, to help everyone stay on the same page

LYNOZYFIC™ (linvoseltamab-gcpt) Injection 5mg | 200mg

SUMMARY

In patients with relapsed or refractory multiple myeloma who had received at least 4 prior treatment regimens, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody,

LYNOZYFIC delivered proven results



LYNOZYFIC uses your own immune system to help fight back against multiple myeloma.



A broad range of patients with relapsed or refractory multiple myeloma participated in the clinical trial for LYNOZYFIC.



While you're being treated with LYNOZYFIC, you and your caregiver should watch for symptoms of CRS, IRR, neurologic problems, infections, and other side effects.

LYNOZYFIC offers the potential for once-every-4-weeks dosing



After about 4 months, you'll receive LYNOZYFIC every 2 weeks. After about 6 months, you may be able to receive LYNOZYFIC once every 4 weeks* and make fewer trips to the doctor for treatment.



Regeneron offers helpful resources to support you and your caregiver during your treatment with LYNOZYFIC.

*Your doctor will decide if your disease is responding well enough to treatment (a very good partial response or better) to switch to once-every-4-weeks dosing.

For more information, resources, and the latest updates:

Visit LYNOZYFIC.com.

IMPORTANT SAFETY INFORMATION (cont'd)

What are the possible side effects of LYNOZYFIC?

LYNOZYFIC may cause serious side effects, including:

- **Infections.** LYNOZYFIC can cause bacterial, viral, or fungal infections that are serious, life-threatening, or that may lead to death. Upper respiratory tract infections and pneumonia are common during treatment with LYNOZYFIC.
  - Your healthcare provider will monitor you for signs and symptoms of infection before and during treatment with LYNOZYFIC.
  - Your healthcare provider may prescribe medicines for you to help prevent infections and treat you as needed if you develop an infection during treatment with LYNOZYFIC.
  - Tell your healthcare provider right away if you develop any signs or symptoms of infection during treatment with LYNOZYFIC, including:
    - fever of 100.4 °F (38 °C) or higher
    - chills
    - cough
    - shortness of breath
    - chest pain
    - sore throat
    - pain during urination
    - feeling weak or generally unwell

Please see additional IMPORTANT SAFETY INFORMATION throughout and accompanying full Prescribing Information, including Boxed WARNING, and Medication Guide for LYNOZYFIC.

LYNOZYFIC™ (linvoseltamab-gcpt) Injection 5mg | 200mg

IMPORTANT SAFETY INFORMATION (cont'd)

What are the possible side effects of LYNOZYFIC? (cont'd)

- **Decreased white blood cell counts.** Decreased white blood cell counts are common during treatment with LYNOZYFIC and can also be severe. Fever can happen with low white blood cell counts and may be a sign that you have an infection. Your healthcare provider will check your blood cell counts before you start treatment and during treatment with LYNOZYFIC, and will treat you as needed.

- **Liver problems.** LYNOZYFIC can cause increased liver enzymes and bilirubin in your blood. These increases can happen with or without you also having CRS. Your healthcare provider will do blood tests to check your liver before starting and during treatment with LYNOZYFIC. Tell your healthcare provider if you develop any of the following signs or symptoms of liver problems:
  - tiredness
  - loss of appetite
  - pain in your right upper stomach-area (abdomen)
  - dark urine
  - yellowing of your skin or the white part of your eyes

The most common side effects of LYNOZYFIC include:

- muscle and bone pain
- cough
- diarrhea
- tiredness or weakness
- nausea
- headache
- shortness of breath

Please see additional IMPORTANT SAFETY INFORMATION throughout and accompanying full Prescribing Information, including Boxed WARNING, and Medication Guide for LYNOZYFIC.

NOTES

YOUR LYNOZYFIC **CALENDAR**

You and your caregiver may use the chart below to keep track of your LYNOZYFIC dosing schedule. Be sure to confirm the dates and times with your care team. This schedule only includes information about your LYNOZYFIC infusion dates. Your doctor may also prescribe other medications.

My LYNOZYFIC Calendar					
Step-up doses			**Once-every-2-weeks dosing**		
Dose 1	Date:	Time:	**Dose 15**	Date:	Time:
Dose 2	Date:	Time:	**Dose 16**	Date:	Time:
Once-a-week dosing			**Dose 17**	Date:	Time:
Dose 3	Date:	Time:	**Dose 18**	Date:	Time:
Dose 4	Date:	Time:	**Dose 19**	Date:	Time:
Dose 5	Date:	Time:	**Continue on once-every-4-weeks or once-every-2-weeks dosing according to your doctor's instructions**		
Dose 6	Date:	Time:			
Dose 7	Date:	Time:	**Dose 20**	Date:	Time:
Dose 8	Date:	Time:	**Dose 21**	Date:	Time:
Dose 9	Date:	Time:	**Dose 22**	Date:	Time:
Dose 10	Date:	Time:	**Dose 23**	Date:	Time:
Dose 11	Date:	Time:	**Dose 24**	Date:	Time:
Dose 12	Date:	Time:	**Dose 25**	Date:	Time:
Dose 13	Date:	Time:	**Dose 26**	Date:	Time:
Dose 14	Date:	Time:	**Dose 27**	Date:	Time:

Your doctor will decide how long you will receive treatment with LYNOZYFIC.

IMPORTANT SAFETY INFORMATION (cont'd)

The most common severe abnormal blood test results with LYNOZYFIC include: low white blood cell counts and low red blood cell counts.

These are not all of the possible side effects of LYNOZYFIC.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see accompanying full Prescribing Information, including Boxed WARNING, and Medication Guide for LYNOZYFIC.

MIX
Paper from responsible sources
FSC® C000000

REGENERON®

LYNOZYFIC™ (linvoseltamab-gcpt) Injection 5mg | 200mg

© 2025 Regeneron Pharmaceuticals, Inc. All rights reserved. US.LIN.24.01.0010 07/25